市场调查报告书
商品编码
1139889
移植物抗宿主病市场:按产品类型,按治疗类型,按最终用户:2021-2031 年全球机会分析和行业预测Graft Versus Host Disease Market By Product Type, By Treatment Type, By End Use : Global Opportunity Analysis and Industry Forecast, 2021-2031 |
2021 年全球移植物抗宿主病市场价值为 29.686 亿美元,到 2031 年将达到 103.753 亿美元,预计 2022 年至 2031 年的复合年增长率为 13.5%。
移植物抗宿主病 (GVHD) 是异基因移植(骨髓移植)后可能发生的疾病。在GVHD中,捐赠的骨髓和外周血干细胞将接受者的身体视为异物,捐赠的细胞和骨髓会攻击身体。 GVHD 有两种形式:急性移植物抗宿主病 (aGVHD) 和慢性移植物抗宿主病 (cGVHD)。
aGVHD 和 cGVHD 的病理生理学仍未完全了解。即损伤肠黏膜和肝臟等宿主组织的调理疗法,激活供体T细胞对抗宿主抗原并随后扩增克隆T细胞,白细胞介素-1(IL-1)和肿瘤坏死因子(TNFα)释放炎症细胞毒性等细胞因子会导致进一步的宿主组织损伤。几种机制有助于 cGVHD 的发展,包括供体来源的同种异体反应性 T 细胞、自身反应性 T 细胞和产生针对宿主的抗体的 B 细胞的持续存在,以及导致终末器官纤维化的慢性炎症机制。涉及。
儘管在移植后免疫抑制治疗方面进行了数十年的研究和改进,移植物抗宿主病 (GVHD) 仍然是异基因造血干细胞移植 (HSCT) 受者发病率和死亡率的重要原因。
COVID-19 大流行正在影响世界各地的各种企业。移植物抗宿主病市场也产生了重大影响。为了阻止 COVID-19 的传播,世界各国政府都实施了严格的规定,包括关闭边境、限制和严格的社会隔离措施。这些措施对全球经济产生了重大影响,影响了各个行业。製药和生物技术公司正在与世界各地的政府合作应对 COVID-19 疫情,从支持疫苗开发到规划药物供应链挑战。目前大约有 115 种候选疫苗和 155 种分子在研发中。
COVID-19 的影响 COVID-19 大流行已经深刻改变了美国和全球的肾移植格局。大流行不仅对受者同种异体移植物和肾移植后的患者生存产生了不利影响,而且还影响了移植物的转诊和上市、器官捐赠率、器官采购和运送、等待名单死亡率以及移植医学的其他方面。
随着肾移植率的下降,器官获取率也在下降。英国报告称,转诊至 OPO 的器官减少了 39%。法国报告说,与往年相比,全死亡器官采购减少了 16%。其中一些下降是由于缺乏测试能力和 COVID-19 测试结果延迟、手术室的可用性有限、强制避免不必要的临床活动以保护人员和防护设备以及该组织面临的采购挑战。
因此,由于移植手术数量的减少,COVID-19 对移植物抗宿主病市场的总体影响仍然是负面的。植入手术需要常规使用可重复使用的器械,并与患者密切接触。这增加了疾病传播的风险。
移植物抗宿主病的增加主要是由于同种异体移植的增加。疾病诊断率的提高和移植物抗宿主病治疗产品的增加也是推动市场增长的因素。
根据器官采购和移植网络的初步数据,2020 年,美国已故捐献者的器官捐赠创下历史新高。共有 12,587 人捐赠了一个或多个器官来拯救或改善他人的生命,比 2019 年增加了 6%。
此外,死者捐赠的大部分增加是由于捐赠者的表现低于传统医疗标准。已故捐赠者最常见的年龄组是 50-64 岁。与 2019 年相比,该类别的 3,726 名捐助者增加了 7.9%。与脑死亡相比,死于心肺功能不全的人的捐赠显着增加,有 3223 名心肺死亡后捐赠者(DCD 捐赠者),比 2019 年的总数增加了 18.6%。
根据器官捐献统计,全国等待器官移植的人数为105988人,而每天等待器官移植的人死亡17人,预计2021年将进行40000例移植手术。完成了。
术后并发症,如计算生物学无法检测到的过敏反应、不利的政府情景、设备的高初始和维护成本、缺乏标准化、缺乏熟练劳动力等,将在预测期内影响市场。预计成为增长的主要障碍。
移植物抗宿主病市场根据产品、诊断、类型、最终用途和地区进行细分。按产品划分,它分为皮质类固醇、单克隆抗体、免疫抑製剂等。按类型分为急性期和慢性期。最终用途分为医院药房、零售药房和在线药房。
The global Graft Versus Host Disease Market was valued at $2,968.6 million in 2021, and is projected to reach $10,375.3 million by 2031, registering a CAGR of 13.5% from 2022 to 2031.
Graft versus host disease (GVHD) is a condition that might occur after an allogeneic transplant (bone marrow transplant). In GVHD, the donated bone marrow or peripheral blood stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body. There are two forms of GVHD: acute graft versus host disease (aGVHD) and chronic graft versus host disease (cGVHD).
The pathophysiology of aGVHD and cGVHD remains incompletely understood. One commonly quoted model suggests three distinct stages in the development of aGVHD: a conditioning regimen, which damages host tissues, including intestinal mucosa and liver; activation of donor T cells against host antigens & subsequent clonal T-cell expansion; and release of inflammatory cytokines such as interleukin 1 (IL-1) & tumor necrosis factor (TNFα), leading to further host tissue damage. Several mechanisms have been implicated in cGVHD pathogenesis, including persistence of donor-derived alloreactive T cells, autoreactive T cells, B cells producing antibodies against the host, and mechanisms of chronic inflammation leading to end organ fibrosis.
Despite decades of research and improvements in post-transplant immunosuppressive therapies, graft-versus-host disease (GVHD) remains a significant cause of morbidity and mortality in allogenic hematopoietic stem-cell transplant (HSCT) recipients.
The COVID-19 pandemic has had an impact on a variety of businesses around the world. The Graft Versus Host Disease Market had a significant impact as well. To halt the spread of COVID-19, governments around the world implemented harsh restrictions such as border locks, lockdowns, and tight social distancing measures. These measures had a significant impact on the global economy, affecting a variety of industries. Pharmaceutical and biotech companies together with governments around the globe work to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline.
Impact of COVID-19: The COVID-19 pandemic has significantly changed the landscape of kidney transplantation in the U.S. and worldwide. In addition to adversely impacting allograft and patient survival in post kidney transplant recipients, the current pandemic has affected all aspects of transplant care, including transplant referrals and listing, organ donation rates, organ procurement and shipping, and waitlist mortality.
As kidney transplantation rates declined, so did organ procurement rates. The UK reported a 39% decrease in referrals of organs to OPOs. France reported a 16% decrease in all deceased organ procurement rates as compared to previous years. Part of these declines were due to procurement challenges faced by transplant programs and organizations, such as insufficient testing capabilities and delayed COVID-19 test results, limited operating room availabilities, and mandates for the avoidance of nonessential clinical activities to preserve personnel and protective equipment.
Therefore, the overall impact of COVID-19 remains negative on graft versus host disease market due to decline in number of transplantation procedure. The transplant procedure requires the routine use of reusable equipment with close contact with patients. This increases the risk of disease transmission.
Increase in number of grafts versus host disease, which arises predominantly due to rise in number of allogenic transplantations. Also, increase in disease diagnosis rate and increase in number of products available for the treatment of graft versus host disease are the factors fueling the growth of the market.
According to preliminary data from the Organ Procurement and Transplantation Network, in 2020 organ donation from deceased donors in the U.S. set an all-time record. A total of 12,587 people provided one or more organs to save and enhance the lives of others, representing an increase of six percent over 2019.
Moreover, much of the increase in deceased donation was made possible by donors representing less traditional medical criteria. The most common age range of deceased donors was 50 to 64. The 3,726 donors in this category increased by 7.9 percent over 2019. Donation increased significantly among individuals who died of cardiorespiratory failure as opposed to brain death; the 3,223 donors after cardiorespiratory death (DCD donors) increased by 18.6 percent over the total in 2019.
According to Organ Donation Statistics, 105,988 number of men, women, and children are on the national transplant waiting list, whereas 17 people die each day waiting for the organ transplant and an estimated 40,000 transplants were performed in 2021.
Complications such as allergic reactions, which cannot be detected by computational biology and other post-surgery complications, unfavorable government scenario, the high initial cost and maintenance costs of the instruments, lack of standardization, and shortage of skilled workforce are expected to be the significant restraints to market growth during the forecast period.
The graft versus host disease market is segmented on the basis of product, diagnosis, types, end use, and region. By product the market is segmented into corticosteroids, monoclonal antibodies, immunosuppressants and others. On the basis of type the segment is divided into acute and chronic. On the basis of end use the segment is divided into hospital pharmacies, retail pharmacies and online pharmacies.
Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the graft versus host disease market are AbbVie, Asahi Kasei, Bristol Myer Squibb, GlaxoSmithKline, Incyte Corporation, Medac GmbH, Merck & co., Novartis, Pfizer and Sanofi.
Key Benefits For Stakeholders
The study provides an in-depth analysis of the graft versus host disease market, and the current graft versus host disease market trends and future estimations to elucidate imminent investment pockets.
It presents a quantitative analysis of the market from 2022 to 2031 to enable stakeholders to capitalize on the prevailing market graft versus host disease market opportunity.
Extensive analysis of the market based on procedures and services assists to understand the trends in the graft versus host disease industry.
Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
Key Market Segments
By Product Type
By Treatment Type
By End Use
By Region